Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Influence of rYopM treatment on IMQ-induced psoriasiform dermatitis

ABSTRACT: Influence of rYopM treatment on IMQ-induced psoriasiform dermatitis

PROVIDER: PRJNA486825 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7723480.fastq.gz	Fastqsanger.gz
	SRR7723481.fastq.gz	Fastqsanger.gz
	SRR7723482.fastq.gz	Fastqsanger.gz
	SRR7723483.fastq.gz	Fastqsanger.gz
	SRR7723484.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

RNA-seq of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:We divided the male C57BL/6 mice into two groups: a non-treatment group and an IMQ-induced psoriasiform dermatitis group. We isolated the C3-C5 ganglia from male mice, then preserved them in RNA stabilization solution. RNA was extracted using Trizol, followed by transcriptome sequencing.

2025-07-31 | GSE276367 | GEO

Single-cell sequencing of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:We divided the e male C57BL/6 mice into two groups: a non-treatment group and an IMQ-induced psoriasiform dermatitis group. The dorsal root ganglia of the mice were extracted, enzymatically digested, and then enriched using Percoll. Subsequently, single-cell RNA sequencing was performed.

2025-07-31 | GSE302755 | GEO

Influence of rYopM treatment on IMQ-induced psoriasiform dermatitis

Project description:RNA-seq of skin of vehicle-treated, IMQ-treated, IMQ+rYopM-treated and IMQ+rYopM_LRR1-3 treated mice.

2021-08-16 | GSE118803 | GEO

RNA-seq of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:RNA-seq of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

| PRJNA1156787 | ENA

Single-cell sequencing of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:Single-cell sequencing of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

| PRJNA1292105 | ENA

Expression data from IMQ-induced psoriasis-like skin inflammation in miR-146a-/- and C57BL6J mice

Project description:miR-146a acts as a negative feedback regulator of inflammation. To investigate the role of miR-146a in psoriasis psoriasiform skin inflammation was indeuced in Mir-146a-/- and wild type mice (C57BL6J) by topical applciation of imiquimod (IMQ)-cream (Aldara). Gene expression profiling (Affymetrix) was used to identify transcriptomic changes associated with psoriasis-like skin inflammation in wild type vs. miR-146a -/-mice. A daily topical dose of 31.25 mg of Aldara cream (5% IMQ) was applied on the right ear of miR-146a -/- and C57BL/6 mice on three consecutive days to induce psorisis-like skin inflammation. Mice were sacrificed at day 4. Ear flaps were collected for total RNA extraction and hybridization on Affymatrix GeneTitan plate format Gene ST 2.1 (mouse).

2016-02-19 | E-GEOD-78057 | biostudies-arrayexpress

Expression data from IMQ-induced psoriasis-like skin inflammation in miR-146a-/- and C57BL6J mice

2016-02-19 | GSE78057 | GEO

Low-input mRNA Sequencing Analysis of Epidermal Langerhans cells (LC) from Murine Imiquimod (IMQ)-Induced Psoriasis-Like Dermatitis

Project description:Purpose: To compare epidermal LC transcriptomes of control group (wild-type IMQ-untreated C57/BL6 mice) and IMQ group (wild-type IMQ-treated C57/BL6 mice). Results: KEGG pathway analysis implied that lesional LCs were highly enriched in several inflammatory signalling pathways, including cytokine-cytokine receptor interactions, Th1, Th2 and Th17 cell differentiation, tumor necrosis factor signalling and IL-17 signalling pathways, complement and coagulation cascades, and NOD-like receptor signalling and PI3K-Akt signalling pathways. Gene set enrichment analysis plots revealed enrichment of cytokine activity, chemoattractant activity, protein lipid complex binding, and low-density lipoprotein particle binding gene sets in LCs from IMQ+ mice compared with IMQ- mice. Conclusions: These results confirmed a proinflammatory role for epidermal LCs in the pathogenesis of psoriasis.

2020-11-28 | GSE162274 | GEO

Microarray expression data from P50 mouse full thickness back skin of C57BL/6 mice - various durations of IMQ treatment and timepoints.

Project description:Imiquimod (IMQ) is a topical therapeutic immune activator that causes psoriasiform inflammation in mice. To determine if IMQ-induced inflammation and gene expression changes depended on the time of day in which treatment is administered, we performed gene expression profiling of dorsal mouse back skin by microarray after different durations of topical 1% IMQ treatment (control = no treatment, 6 hr, 24 hr, and 5 days of IMQ treatment) at different times of day (ZT01, ZT07, ZT09 = day-time treatment; ZT13 and ZT19 = night-time treatment). We also performed a time course after IMQ treatment by collecting mouse back skin after 0 (no treatment), 1, 2, 4, 6, and 24 hours post-treatment. Lastly, we determined gene expression changes in response to IMQ in mice deleted for the core circadian clock gene, Bmal1, after 0 (no treatment) and 24 hours post-1% IMQ compared to Wt (both treated and collected during the daytime at ZT09). The results of this study are important as they show that IMQ-induced activation of interferon sensitive genes are diurnal in Wt mice after 6 hours and 24 hours but not after 5 consecutive treatments. Furthermore, we find that interferon sensitive genes are induced more robustly in the skin of Bmal1 KO mice after 24 hr IMQ compared to Wt mice. These results are important for further understanding how the circadian clock regulates immune activation in response to the theraputic agent IMQ. In this dataset, we include the expression data obtained from 28 microarray samples, all of which were generated from whole back skin RNA samples pooled from 5-7 mice per sample.

2020-03-30 | GSE142165 | GEO

KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease

Project description:Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease hypothesized to promote inflammation via cleavage of protease-activated receptors (PAR)1 and PAR2. KLK6 levels are elevated in multiple inflammatory and autoimmune conditions, but no definitive role in pathogenesis has been established. Here, we show that skin-targeted overexpression of KLK6 causes generalized, severe psoriasiform dermatitis with spontaneous development of debilitating psoriatic arthritis-like joint disease. The psoriatic skin and joint phenotypes are reversed by normalization of skin KLK6 levels and attenuated following genetic elimination of PAR1 but not PAR2. Conservation of this regulatory pathway was confirmed in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin from psoriasis patients. Beyond defining a critical role for KLK6-PAR1 signaling in promoting psoriasis, our results demonstrate that KLK6-PAR1-mediated inflammation in the skin alone is sufficient to drive inflammatory joint disease. Further, we identify PAR1 as a promising cytokine-independent target in therapy of psoriasis and psoriatic arthritis.

2020-03-25 | GSE144312 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data